Ischemic preconditioning increases myocardial O-GlcNAc glycosylation

Rebekka Vibjerg Jensen, Jacob Johnsen, Steen Buus Kristiansen, Natasha E Zachara, Hans Erik Bøtker

Research output: Contribution to journalArticle

Abstract

Objectives. Through the hexosamine biosynthetic pathway (HBP) proteins are modified by O-linked-β-N-acetylglucosamine (O-GlcNAc), which acts as a stress sensor. Augmentation of O-GlcNAc confers cardioprotection against ischemia- reperfusion injury, but its role in ischemic preconditioning (IPC) is unknown. Azaserine and alloxan are unspecific blockers of the HBP and have been used to block the cardioprotective effects of O-GlcNAc. We hypothesized that IPC reduces infarct size and increases O-GlcNAc levels in hearts subjected to ischemia-reperfusion injury, and that these effects could be blocked by azaserine and alloxan. Design. Isolated rat hearts subjected to 40 min global ischemia and 120 min reperfusion were randomized to control, IPC, IPC + azaserine or alloxan, or control + azaserine or alloxan. The effects on infarct size, hemodynamic recovery, myocardial O-GlcNAc levels, and HBP enzyme activities were determined. Results. IPC reduced infarct size, increased O-GlcNAc levels, O-GlcNAc-transferase levels, and O-GlcNAc-transferase activity. Azaserine and alloxan did not block the effect of IPC on O-GlcNAc levels and O-GlcNAc-transferase activity. Conclusions. IPC increased O-GlcNAc levels though increased O-GlcNAc-transferase expression and activity. Azaserine and alloxan failed to block these effects presumably due to poor specificity and sensitivity of the blockers, and IPC-mediated cardioprotection may therefore still be dependent on O-GlcNAc.

Original languageEnglish (US)
Pages (from-to)168-174
Number of pages7
JournalScandinavian Cardiovascular Journal
Volume47
Issue number3
DOIs
StatePublished - 2013

Fingerprint

Myocardial Ischemic Preconditioning
Ischemic Preconditioning
Azaserine
Glycosylation
Alloxan
Hexosamines
Biosynthetic Pathways
Reperfusion Injury
Acetylglucosamine
Recombinant Proteins
Reperfusion
Ischemia
Hemodynamics
Sensitivity and Specificity

Keywords

  • Alloxan
  • Azaserine
  • Ischemia-reperfusion injury
  • Ischemic preconditioning
  • O-GlcNAc

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Ischemic preconditioning increases myocardial O-GlcNAc glycosylation. / Jensen, Rebekka Vibjerg; Johnsen, Jacob; Kristiansen, Steen Buus; Zachara, Natasha E; Bøtker, Hans Erik.

In: Scandinavian Cardiovascular Journal, Vol. 47, No. 3, 2013, p. 168-174.

Research output: Contribution to journalArticle

Jensen, Rebekka Vibjerg ; Johnsen, Jacob ; Kristiansen, Steen Buus ; Zachara, Natasha E ; Bøtker, Hans Erik. / Ischemic preconditioning increases myocardial O-GlcNAc glycosylation. In: Scandinavian Cardiovascular Journal. 2013 ; Vol. 47, No. 3. pp. 168-174.
@article{91b4c9daff5d462ab9461bdbb8034cda,
title = "Ischemic preconditioning increases myocardial O-GlcNAc glycosylation",
abstract = "Objectives. Through the hexosamine biosynthetic pathway (HBP) proteins are modified by O-linked-β-N-acetylglucosamine (O-GlcNAc), which acts as a stress sensor. Augmentation of O-GlcNAc confers cardioprotection against ischemia- reperfusion injury, but its role in ischemic preconditioning (IPC) is unknown. Azaserine and alloxan are unspecific blockers of the HBP and have been used to block the cardioprotective effects of O-GlcNAc. We hypothesized that IPC reduces infarct size and increases O-GlcNAc levels in hearts subjected to ischemia-reperfusion injury, and that these effects could be blocked by azaserine and alloxan. Design. Isolated rat hearts subjected to 40 min global ischemia and 120 min reperfusion were randomized to control, IPC, IPC + azaserine or alloxan, or control + azaserine or alloxan. The effects on infarct size, hemodynamic recovery, myocardial O-GlcNAc levels, and HBP enzyme activities were determined. Results. IPC reduced infarct size, increased O-GlcNAc levels, O-GlcNAc-transferase levels, and O-GlcNAc-transferase activity. Azaserine and alloxan did not block the effect of IPC on O-GlcNAc levels and O-GlcNAc-transferase activity. Conclusions. IPC increased O-GlcNAc levels though increased O-GlcNAc-transferase expression and activity. Azaserine and alloxan failed to block these effects presumably due to poor specificity and sensitivity of the blockers, and IPC-mediated cardioprotection may therefore still be dependent on O-GlcNAc.",
keywords = "Alloxan, Azaserine, Ischemia-reperfusion injury, Ischemic preconditioning, O-GlcNAc",
author = "Jensen, {Rebekka Vibjerg} and Jacob Johnsen and Kristiansen, {Steen Buus} and Zachara, {Natasha E} and B{\o}tker, {Hans Erik}",
year = "2013",
doi = "10.3109/14017431.2012.756984",
language = "English (US)",
volume = "47",
pages = "168--174",
journal = "Scandinavian Cardiovascular Journal",
issn = "1401-7431",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Ischemic preconditioning increases myocardial O-GlcNAc glycosylation

AU - Jensen, Rebekka Vibjerg

AU - Johnsen, Jacob

AU - Kristiansen, Steen Buus

AU - Zachara, Natasha E

AU - Bøtker, Hans Erik

PY - 2013

Y1 - 2013

N2 - Objectives. Through the hexosamine biosynthetic pathway (HBP) proteins are modified by O-linked-β-N-acetylglucosamine (O-GlcNAc), which acts as a stress sensor. Augmentation of O-GlcNAc confers cardioprotection against ischemia- reperfusion injury, but its role in ischemic preconditioning (IPC) is unknown. Azaserine and alloxan are unspecific blockers of the HBP and have been used to block the cardioprotective effects of O-GlcNAc. We hypothesized that IPC reduces infarct size and increases O-GlcNAc levels in hearts subjected to ischemia-reperfusion injury, and that these effects could be blocked by azaserine and alloxan. Design. Isolated rat hearts subjected to 40 min global ischemia and 120 min reperfusion were randomized to control, IPC, IPC + azaserine or alloxan, or control + azaserine or alloxan. The effects on infarct size, hemodynamic recovery, myocardial O-GlcNAc levels, and HBP enzyme activities were determined. Results. IPC reduced infarct size, increased O-GlcNAc levels, O-GlcNAc-transferase levels, and O-GlcNAc-transferase activity. Azaserine and alloxan did not block the effect of IPC on O-GlcNAc levels and O-GlcNAc-transferase activity. Conclusions. IPC increased O-GlcNAc levels though increased O-GlcNAc-transferase expression and activity. Azaserine and alloxan failed to block these effects presumably due to poor specificity and sensitivity of the blockers, and IPC-mediated cardioprotection may therefore still be dependent on O-GlcNAc.

AB - Objectives. Through the hexosamine biosynthetic pathway (HBP) proteins are modified by O-linked-β-N-acetylglucosamine (O-GlcNAc), which acts as a stress sensor. Augmentation of O-GlcNAc confers cardioprotection against ischemia- reperfusion injury, but its role in ischemic preconditioning (IPC) is unknown. Azaserine and alloxan are unspecific blockers of the HBP and have been used to block the cardioprotective effects of O-GlcNAc. We hypothesized that IPC reduces infarct size and increases O-GlcNAc levels in hearts subjected to ischemia-reperfusion injury, and that these effects could be blocked by azaserine and alloxan. Design. Isolated rat hearts subjected to 40 min global ischemia and 120 min reperfusion were randomized to control, IPC, IPC + azaserine or alloxan, or control + azaserine or alloxan. The effects on infarct size, hemodynamic recovery, myocardial O-GlcNAc levels, and HBP enzyme activities were determined. Results. IPC reduced infarct size, increased O-GlcNAc levels, O-GlcNAc-transferase levels, and O-GlcNAc-transferase activity. Azaserine and alloxan did not block the effect of IPC on O-GlcNAc levels and O-GlcNAc-transferase activity. Conclusions. IPC increased O-GlcNAc levels though increased O-GlcNAc-transferase expression and activity. Azaserine and alloxan failed to block these effects presumably due to poor specificity and sensitivity of the blockers, and IPC-mediated cardioprotection may therefore still be dependent on O-GlcNAc.

KW - Alloxan

KW - Azaserine

KW - Ischemia-reperfusion injury

KW - Ischemic preconditioning

KW - O-GlcNAc

UR - http://www.scopus.com/inward/record.url?scp=84878145030&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878145030&partnerID=8YFLogxK

U2 - 10.3109/14017431.2012.756984

DO - 10.3109/14017431.2012.756984

M3 - Article

C2 - 23301939

AN - SCOPUS:84878145030

VL - 47

SP - 168

EP - 174

JO - Scandinavian Cardiovascular Journal

JF - Scandinavian Cardiovascular Journal

SN - 1401-7431

IS - 3

ER -